CHICAGO, August 21, 2026, 05:36 EDT — Nasdaq premarket trading was open while U.S. cash markets remained closed.
- Tempus rose 35.0% over Wednesday and Thursday, increasing its equity value by roughly $3.03 billion.
- The rise is about double the $1.5 billion amount of its ongoing Personalis acquisition.
- The average Wall Street target of $62.92 is currently 5.6% lower than Thursday’s closing price.
Tempus AI, Inc. NASDAQ:TEM saw its market capitalisation increase by roughly $3.03 billion since the close on Tuesday. Shares climbed 24.1% on Wednesday, followed by an additional 8.8% advance to $66.65 on Thursday. The stock surged 35.0% over the two sessions.
The rise amounts to nearly double the $1.5 billion enterprise value of Tempus’s planned purchase of Personalis, Inc. NASDAQ:PSNL. As a result, investors are valuing more than just the acquisition. They are factoring in potential growth across the broader cancer monitoring and drug discovery sectors.
The trigger for the move was external to Tempus. Moderna, Inc. NASDAQ:MRNA and Merck & Co., Inc. NYSE:MRK announced their Phase 3 melanoma trial achieved both co-primary endpoints. Personalis provides the genomic sequencing technology used in Moderna’s individualized cancer vaccine program. The firms have yet to disclose specific efficacy data.
| Tempus valuation reset | Stock price | Change in day | Projected market capitalisation |
|---|---|---|---|
| Close August 18 | $49.36 | — | $8.66 billion |
| Close August 19 | $61.25 | +24.1% | $10.74 billion |
| Close August 20 | $66.65 | +8.8% | $11.69 billion |
| Change over two sessions | +$17.29 | +35.0% | +$3.03 billion |
The transaction valuation is steep. Personalis reported $22.4 million in revenue for the second quarter. When annualized, this values the purchase at roughly 16.7 times sales, prior to factoring in synergies. Clinical revenue reached only $2.6 million, although that represents a 442% year-on-year increase.
| Deal valuation test | Verified figure | Investor reading |
|---|---|---|
| Personalis enterprise value | $1.50 billion | Stated transaction value |
| Tempus two-session value gain | $3.03 billion | 2.02 times the deal’s size |
| Personalis Q2 revenue | $22.4 million | Roughly 16.7 times the annualized revenue |
| Merger downside threshold | $46.00 per TEM share | Thursday’s close represented a 44.9% premium |
Tempus has greater size to support that valuation. Second-quarter revenue increased by 22% to $382.5 million. Adjusted EBITDA turned positive at $8.0 million, with cash totaling $820.7 million. The company forecasts approximately $1.60 billion in revenue for 2026.
| Operating comparison | Tempus AI | Personalis |
|---|---|---|
| Q2 revenue | $382.5 million | $22.4 million |
| Revenue growth | 22% | 30% |
| Profitability marker | $8.0 million adjusted EBITDA | Not provided in statement |
| Cash at quarter-end | $820.7 million | $212.7 million |
| Clinical momentum | Not individually reported | 10,384 tests, up 199% |
Personalis is seeing growth primarily from its molecular residual disease testing segment. Clinical volume for the second quarter almost tripled, reaching 10,384 tests. CEO Chris Hall stated that over 1,400 doctors are now ordering NeXT Personal. The rate of physician adoption is more significant than any individual trial result.
Eric Lefkofsky, CEO of Tempus, described molecular residual disease as “a large and rapidly growing market.” The company puts the potential market size at over $20 billion. The acquisition aims to merge Personalis’s tumor-informed testing with Tempus’s clinical data resources and distribution network. Tempus acquisition announcement
The deal will primarily be paid in stock. Shareholders of Personalis can choose to receive up to half of their payment in cash, depending on proration. The variable exchange ratio has a maximum of 0.3356 Tempus shares per Personalis share. The transaction is expected to close towards the end of the year or in early 2027.
The rally reignited discussion among analysts. On Thursday, BTIG’s Mark Massaro raised his price target to $80 from $70 while maintaining a Buy rating. However, the consensus average target is still under the current market price.
| Analyst recommendations | Rating | Target | Date |
|---|---|---|---|
| BTIG, Mark Massaro | Buy | $80 | August 20 |
| JPMorgan, Casey Woodring | Hold | $45 | August 4 |
| Piper Sandler, David Westenberg | Hold | $56 | August 4 |
| H.C. Wainwright, Yi Chen | Buy | $56 | August 4 |
| Guggenheim, Subbu Nambi | Buy | $65 | August 3 |
| 15-analyst consensus | 8 Buy, 7 Hold, 0 Sell | $62.92 average | Past three months |
Tempus is priced at $66.65, trading 5.6% higher than the average analyst target. The stock is valued at approximately 7.5 times management’s projected 2026 revenue midpoint. This offers minimal margin for delays in integration or reduced demand for testing.
Risks: Phase 3 efficacy information has not yet been released. The acquisition awaits approval from shareholders and regulators. Personalis holds the right to terminate under certain terms if Tempus drops under $46. Both parties also face exposure to fluctuations in stock value through the stock consideration component.
The next step is execution. Tempus needs to translate a clinical readout into ongoing test volume. Thursday’s share price has already baked in significant success.
